Skip to main content

Table 4 Patients characteristics who received LEN without del[5q] by MC (N = 42)

From: Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Case Age (y.o.) Sex Diagnosis IPSS Therapy Response MC FISH SNP-A   
1 73 M RAEB-2 INT-2 LEN/AZA CR N N   Gain 4q13.2
2 75 M RAEB-1 INT-1 LEN/AZA CR N trisomy 8 9% Gain 8q11.1q11.21
           UPD 11q14.1q21
3 62 M MDS/MP N-U INT-1 LEN/AZA PR N N   UPD 1pterp32.3
           UPD 3p21.31p21.1
4 68 M RAEB-2 HIGH LEN/AZA NR complex karyotype, including trisomy 8, del[7q], del[12], and del[20] del[7q] 68% Gain 8
         del[20q] 60% Loss 11p14.3p13
         trisomy 8 41% Loss 12p12.3p11.21
           Loss 12q21.1q21.31
           Loss 16q22.3q24.3
           Loss 1p22.2p22.1
           Loss 20q11.2q13.33
           Loss 21q11.2q21.1
           Loss 2q31.3q32.1
           Loss 6q23.3
           Gain 7q11.21q11.22
           Loss 7q22.1q36.2
5 68 M RAEB-2 INT-2 LEN/AZA CR 47,XY,+8[6] trisomy 8 9% Gain 14q11.1q11.2
           UPD 19p13.11p12
           Gain 8p23.3q24.3
6 73 M CMML-1 NE LEN PR N del[20q] 10% UPD 9pterp22.2
7 67 M PMF NE LEN PR N N   Loss 11q23.3
8 66 M RCMD LOW LEN HI 46,XY,del(20)(q11q13)[2]/4 6,XY[18] del[20q] 17% Gain 8q11.1q11.23
9 69 M RAEB-1 INT-2 LEN/AZA CR N N   NE  
10 64 M MDS/MP N-U NE LEN CR N N   N  
11 79 F CMML-2 NE LEN/AZA HI 47,XX,+8[20] trisomy 8 42% Gain 8
12 62 F RAEB-2 INT-2 LEN/AZA CR N N   N  
13 62 F RARS INT-1 LEN NR 46,XX,add(15)(p11.1),add(2 2)(p11.2)[3]/47,idem,+19[19]. del[7q] 11% Gain 19
         del[7] 6% Gain 3q26.1
           Gain 4p16.2
14 72 M MDS/MPN-U INT-2 LEN PR no growth del[5q] 8% Loss 20q11.1q13.12
         del[20q] 35% Loss 2p21p24.1
           Loss 8q11.23q12.1
           Gain 9p12pter
15 63 M RAEB-2 NE LEN/AZA CR N N   Gain 12q24.32
           Gain 8q11.1
16 81 F RAEB-2 INT-2 LEN/AZA NR N N   N  
17 69 M CMML-2 - LEN/AZA NR N NE   Loss 2p22.3
18 46 M PMF - LEN NR balanced translocation at chromosomes 2 and 22 NE   UPD 14q31.3q32.33
           Gain 9p24.3p11.1
19 70 F sAML - LEN (High dose) NR N del[5q] 33% Loss 5q31.2
20 65 F RARS LOW LEN CR N NE   N  
21 70 M CMML-1 INT-1 LEN HI N N   UPD 7q22.1qter
22 83 M RARS LOW LEN HI N N   N  
23 83 M RARS INT-1 LEN NR N NE   N  
24 71 M MDS-U INT-1 LEN NE N NE   Loss 15q14
25 69 M RARS LOW LEN NR N NE   N  
26 76 M RA INT-1 LEN NR N NE   Loss 3p22.3
27 68 M RA INT-1 LEN NR N NE   Loss 21q21.2
           Gain 3p14.1
           Loss 11q14.3
28 59 M RARS LOW LEN NR N NE   N  
29 73 F RA LOW LEN NR N NE   N  
30 78 F RARS LOW LEN NE N NE   UPD 3q21.3qter
31 78 M RAEB-1 INT-2 LEN NR 47,XY,+19 NE   Gain 19
32 80 M RAEB-1 INT-1 LEN NE N NE   Loss 17q11.2
           UPD 8p11.2qter
33 79 F RARS INT-1 LEN HI N NE   N  
34 73 F RARS LOW LEN HI N NE   Loss 18p11.32
35 78 F sAML - LEN NR 46,XX,t(3;3) NE   Loss 3q26.1
36 80 M RAEB-2 INT-2 LEN NR N NE   Loss 22q13.2
37 69 M RARS LOW LEN HI N NE   N  
38 59 F RA LOW LEN HI N NE   N  
39 62 F RARS LOW LEN NE N NE   Gain 6p21.32
40 82 M RARS INT-1 LEN NR 46,XY,del(20)(q11.2) NE   Loss 20q11.2q13.2
41 53 M RARS LOW LEN HI N NE N   
42 56 F RA INT-1 LEN HI N NE   Loss 9p21.2
           Gain 1p21.1
  1. Abbreviation: M male; F female; RAEB refractory anemia with excess blasts; MDS/MPN-U myelodysplastic syndromes/myeloproliferative neoplasm, unclassifiable; CMML chronic myelomonocytic leukemia; PMF primary myelofibrosis; RCMD refractory cytopenias with multilineage dysplasia; RARS refractory anemia with ring sideroblasts; sAML secondary acute myeloid leukemia; MDS-U, MDS unclassifiable; RA refractory anemia; LEN lenalidomide; AZA azacitidine; N normal; UPD uniparental disomy; NE not evaluated.